Premium
Assessment of a potential tumor‐seeking manganese metalloporphyrin contrast agent in a mouse model
Author(s) -
Takehara Yasuo,
Sakahara Harumi,
Masunaga Hatsuko,
Isogai Satoshi,
Kodaira Nami,
Sugiyama Masahiro,
Takeda Hiroyasu,
Saga Tsuneo,
Nakajima Susumu,
Sakata Isao
Publication year - 2002
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.10109
Subject(s) - biodistribution , clearance , manganese , magnetic resonance imaging , chemistry , nuclear medicine , contrast (vision) , nuclear magnetic resonance , pathology , medicine , radiology , physics , urology , optics , biochemistry , organic chemistry , in vitro
The performance of a newly developed potential tumor‐seeking magnetic resonance (MR) contrast agent α‐Aqua‐13,17‐bis(1‐carboxypropionyl) carbamoylethyl‐3,8‐bis(1‐phenethyloxyethyl)‐β‐hydroxy‐2,7,12,18‐tetramethyl‐porphyrinato manganese (III) (HOP‐8P) was tested using a mouse model. Tumor‐bearing (SCC‐VII) mice were imaged using a 1.5T MR imager before and after intravenous administration of 0.1 mmol/kg of HOP‐8P. A biodistribution analysis was performed using an optical emission spectrometer. Significant enhancement of the transplanted tumor was observed in MR images 24 h after intravenous injection of HOP‐8P. The biodistribution assessment of manganese also correlated with the results of the imaging study. During the 24‐h period following contrast administration, HOP‐8P was consistently cleared from the circulation, liver, kidneys, and muscle; however, it was progressively accumulated within the tumor. HOP‐8P is a promising tumor‐seeking metalloporphyrin MR contrast agent with a wide imaging window. Magn Reson Med 47:549–553, 2002. © 2002 Wiley‐Liss, Inc.